1.
s.l; s.n; 1997. 4 p. tab.
No convencional
en Inglés
| Sec. Est. Saúde SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, Sec. Est. Saúde SP
| ID: biblio-1237211
Asunto(s)
Antiinfecciosos/efectos adversos , Antiinfecciosos/uso terapéutico , Dapsona/uso terapéutico , Esquema de Medicación , Leprostáticos/efectos adversos , Leprostáticos/uso terapéutico , Lepra Lepromatosa/patología , Lepra Lepromatosa/tratamiento farmacológico , Ofloxacino/efectos adversos , Ofloxacino/uso terapéutico , Quimioterapia Combinada , Recurrencia , Rifampin/efectos adversos , Rifampin/uso terapéutico , Estudios de Seguimiento
2.
Int. j. lepr. other mycobact. dis
; 64(2): 142-145, June 1996. tab
Artículo
en Inglés
| Sec. Est. Saúde SP, SESSP-ILSLACERVO, Sec. Est. Saúde SP
| ID: biblio-1226616
RESUMEN
The minimal effective dosages (MEDs) of ofloxacin (OFLO) and sparfloxacin (SPFX) against 10 isolates of Mycobacterium leprae were measured in the mouse foot pad system. The drugs were administered either by gavage or by incorporation into the mouse diet in a range of concentrations. The results demonstrated that the MEDs of OFLO were 4 to 5 times higher than those of SPFX, thus confirming that, on a weight-to-weight basis, the anti-M. leprae activity of SPFX was significantly greater than that of OFLO. The MEDs of OFLO/SPFX measured by gavage were 20 times lower than those measured by incorporating the drug into the mouse diet.